Radiopharm Theranostics Limited Sponsored ADR RADX 深 滬
等待開盤 03-26 09:30:00 美东时间
4.33
+0.190
+4.59%
華盛通- 最 高4.365
- 今 開3.90
- 成交量 22.32万股
- 最 低 3.90
- 昨 收 4.14
- 總市值 5115.48万
- 52周最高 16.25
- 市盈率 靜 --
- 換手率 1.89%
- 52周最低 3.4962
- 委 比 88.50%
- 總股本 1181.41万
- 歷史最高 50.82
- 量 比 0.15
- 振 幅 11.23%
- 歷史最低 3.4962
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with final readout expected by June.
03-24 22:56
Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial
Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
03-24 19:14
美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%，Epsium Enterprise涨20.73%
Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%；Epsium Enterprise涨20.73%；网络齿轮通信涨14.73%
03-24 09:03
Radiopharm’s RAD101 Hits 90% Concordance in Phase 2b Brain Metastases Trial
An update from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. ...
03-24 06:48
Radiopharm Theranostics Doses First Participant In Phase 1/2 Clinical Study Of 177Lu-Betabart
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
02-24 20:36
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
Radiopharm Theranostics announced the dosing of the first patient in its Phase 1/2a clinical trial for 177Lu-Betabart (RV-01), a radiotherapeutic targeting B7-H3. RV-01, developed by Radiopharm Ventures (joint venture with MD Anderson Cancer Center), has shown tumor shrinkage and prolonged survival in preclinical studies. The trial aims to evaluate safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity, with the goal of...
02-24 12:30
Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of
01-28 20:09
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics reported interim results from its Phase 2b clinical trial of RAD 101, with 92% of evaluable participants achieving MRI concordance. Additional interim data from Phase 1 trials of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. The company ended December 2025 with a cash balance of approximately $34.52 million, providing runway into 2027 to advance its pipeline. RAD 202 and RAD 204 showed promising sa...
01-28 12:00
Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance
01-12 20:07
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Radiopharm Ventures LLC, a joint venture between the University of Texas MD Anderson Cancer Center and Radiopharm Theranostics, was established in 2022. The company's lead candidate, Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase 1 therapeutic trial in multiple solid tumors, with the first patient expected to be dosed in Q1 2026. This marks the first global clinical trial targeting B7H3 with a systemic ...
01-12 12:00
